Prospective Validation of Pentraxin-3 as a Novel Serum Biomarker to Predict the Risk of Prostate Cancer in Patients Scheduled for Prostate Biopsy
Purpose: To test and internally validate serum Pentraxin-3 (PTX3) levels as a potential PCa biomarker to predict prostate biopsy (PBx) results. Materials and Methods: Serum PSA and serum PTX3 were prospectively assessed in patients scheduled for PBx at our Institution due to increased serum PSA leve...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/7/1611 |
| _version_ | 1797539309269549056 |
|---|---|
| author | Ugo Giovanni Falagario Gian Maria Busetto Giuseppe Stefano Netti Francesca Sanguedolce Oscar Selvaggio Barbara Infante Elena Ranieri Giovanni Stallone Giuseppe Carrieri Luigi Cormio |
| author_facet | Ugo Giovanni Falagario Gian Maria Busetto Giuseppe Stefano Netti Francesca Sanguedolce Oscar Selvaggio Barbara Infante Elena Ranieri Giovanni Stallone Giuseppe Carrieri Luigi Cormio |
| author_sort | Ugo Giovanni Falagario |
| collection | DOAJ |
| description | Purpose: To test and internally validate serum Pentraxin-3 (PTX3) levels as a potential PCa biomarker to predict prostate biopsy (PBx) results. Materials and Methods: Serum PSA and serum PTX3 were prospectively assessed in patients scheduled for PBx at our Institution due to increased serum PSA levels or abnormal digital rectal examination. Uni- and multivariable logistic regression analysis, area under the receiver operating characteristic curve (AUC), and decision curve analysis (DCA), were used to test the accuracy of serum PTX3 in predicting anyPCa and clinically significant PCa (csPCa) defined as Gleason Grade (GG) ≥ 2. Results: Among the 455 eligible patients, PCa was detected in 49% and csPCa in 25%. During univariate analysis, PTX3 outperformed other variables in predicting both anyPCa and csPCa. The addition of PTX3 to multivariable models based on standard clinical variables, significantly increased each model’s predictive accuracy for anyPCa (AUC from 0.73 to 0.82; <i>p</i> < 0.001) and csPCa (AUC from 0.79 to 0.83; <i>p</i> < 0.001). At DCA, PTX3, and PTX3, density showed higher net benefit than PSA and PSA density and increased the net benefit of multivariable models in deciding when to perform PBx. Conclusions: Serum PTX3 levels might be of clinical utility in predicting prostate biopsy results. Should our findings be confirmed, this novel reflex test could be used to reduce the number and burden of unnecessary prostate biopsies. |
| first_indexed | 2024-03-10T12:44:09Z |
| format | Article |
| id | doaj.art-12d31e3209d145ccb8f7e413cc841f59 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T12:44:09Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-12d31e3209d145ccb8f7e413cc841f592023-11-21T13:35:38ZengMDPI AGCancers2072-66942021-03-01137161110.3390/cancers13071611Prospective Validation of Pentraxin-3 as a Novel Serum Biomarker to Predict the Risk of Prostate Cancer in Patients Scheduled for Prostate BiopsyUgo Giovanni Falagario0Gian Maria Busetto1Giuseppe Stefano Netti2Francesca Sanguedolce3Oscar Selvaggio4Barbara Infante5Elena Ranieri6Giovanni Stallone7Giuseppe Carrieri8Luigi Cormio9Department of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, ItalyDepartment of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, ItalyClinical Pathology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, ItalyDepartment of Pathology, University of Foggia, 71122 Foggia, ItalyDepartment of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, ItalyNephrology Dialysis and Transplantation Unit, University of Foggia, 71122 Foggia, ItalyClinical Pathology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, ItalyNephrology Dialysis and Transplantation Unit, University of Foggia, 71122 Foggia, ItalyDepartment of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, ItalyDepartment of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, ItalyPurpose: To test and internally validate serum Pentraxin-3 (PTX3) levels as a potential PCa biomarker to predict prostate biopsy (PBx) results. Materials and Methods: Serum PSA and serum PTX3 were prospectively assessed in patients scheduled for PBx at our Institution due to increased serum PSA levels or abnormal digital rectal examination. Uni- and multivariable logistic regression analysis, area under the receiver operating characteristic curve (AUC), and decision curve analysis (DCA), were used to test the accuracy of serum PTX3 in predicting anyPCa and clinically significant PCa (csPCa) defined as Gleason Grade (GG) ≥ 2. Results: Among the 455 eligible patients, PCa was detected in 49% and csPCa in 25%. During univariate analysis, PTX3 outperformed other variables in predicting both anyPCa and csPCa. The addition of PTX3 to multivariable models based on standard clinical variables, significantly increased each model’s predictive accuracy for anyPCa (AUC from 0.73 to 0.82; <i>p</i> < 0.001) and csPCa (AUC from 0.79 to 0.83; <i>p</i> < 0.001). At DCA, PTX3, and PTX3, density showed higher net benefit than PSA and PSA density and increased the net benefit of multivariable models in deciding when to perform PBx. Conclusions: Serum PTX3 levels might be of clinical utility in predicting prostate biopsy results. Should our findings be confirmed, this novel reflex test could be used to reduce the number and burden of unnecessary prostate biopsies.https://www.mdpi.com/2072-6694/13/7/1611prostate cancerprostate biopsybiomarkersdecision curve analysispentraxin 3 |
| spellingShingle | Ugo Giovanni Falagario Gian Maria Busetto Giuseppe Stefano Netti Francesca Sanguedolce Oscar Selvaggio Barbara Infante Elena Ranieri Giovanni Stallone Giuseppe Carrieri Luigi Cormio Prospective Validation of Pentraxin-3 as a Novel Serum Biomarker to Predict the Risk of Prostate Cancer in Patients Scheduled for Prostate Biopsy Cancers prostate cancer prostate biopsy biomarkers decision curve analysis pentraxin 3 |
| title | Prospective Validation of Pentraxin-3 as a Novel Serum Biomarker to Predict the Risk of Prostate Cancer in Patients Scheduled for Prostate Biopsy |
| title_full | Prospective Validation of Pentraxin-3 as a Novel Serum Biomarker to Predict the Risk of Prostate Cancer in Patients Scheduled for Prostate Biopsy |
| title_fullStr | Prospective Validation of Pentraxin-3 as a Novel Serum Biomarker to Predict the Risk of Prostate Cancer in Patients Scheduled for Prostate Biopsy |
| title_full_unstemmed | Prospective Validation of Pentraxin-3 as a Novel Serum Biomarker to Predict the Risk of Prostate Cancer in Patients Scheduled for Prostate Biopsy |
| title_short | Prospective Validation of Pentraxin-3 as a Novel Serum Biomarker to Predict the Risk of Prostate Cancer in Patients Scheduled for Prostate Biopsy |
| title_sort | prospective validation of pentraxin 3 as a novel serum biomarker to predict the risk of prostate cancer in patients scheduled for prostate biopsy |
| topic | prostate cancer prostate biopsy biomarkers decision curve analysis pentraxin 3 |
| url | https://www.mdpi.com/2072-6694/13/7/1611 |
| work_keys_str_mv | AT ugogiovannifalagario prospectivevalidationofpentraxin3asanovelserumbiomarkertopredicttheriskofprostatecancerinpatientsscheduledforprostatebiopsy AT gianmariabusetto prospectivevalidationofpentraxin3asanovelserumbiomarkertopredicttheriskofprostatecancerinpatientsscheduledforprostatebiopsy AT giuseppestefanonetti prospectivevalidationofpentraxin3asanovelserumbiomarkertopredicttheriskofprostatecancerinpatientsscheduledforprostatebiopsy AT francescasanguedolce prospectivevalidationofpentraxin3asanovelserumbiomarkertopredicttheriskofprostatecancerinpatientsscheduledforprostatebiopsy AT oscarselvaggio prospectivevalidationofpentraxin3asanovelserumbiomarkertopredicttheriskofprostatecancerinpatientsscheduledforprostatebiopsy AT barbarainfante prospectivevalidationofpentraxin3asanovelserumbiomarkertopredicttheriskofprostatecancerinpatientsscheduledforprostatebiopsy AT elenaranieri prospectivevalidationofpentraxin3asanovelserumbiomarkertopredicttheriskofprostatecancerinpatientsscheduledforprostatebiopsy AT giovannistallone prospectivevalidationofpentraxin3asanovelserumbiomarkertopredicttheriskofprostatecancerinpatientsscheduledforprostatebiopsy AT giuseppecarrieri prospectivevalidationofpentraxin3asanovelserumbiomarkertopredicttheriskofprostatecancerinpatientsscheduledforprostatebiopsy AT luigicormio prospectivevalidationofpentraxin3asanovelserumbiomarkertopredicttheriskofprostatecancerinpatientsscheduledforprostatebiopsy |